Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

p>About the Roche/InterMune Collaboration

In October 2006, Roche and InterMune announced an exclusive worldwide collaboration to develop and commercialize products from InterMune's HCV protease inhibitor program, including ITMN-191. The companies also collaborate on a research program to identify, develop and commercialize novel second-generation HCV protease inhibitors.

At closing, InterMune received from Roche an upfront payment of $60 million, and in 2007 received a $10 million manufacturing milestone and a $10 million development milestone. In addition to the $15 million milestone being announced today, assuming the continued successful development and commercialization of ITMN-191 in the United States and other countries, InterMune could potentially receive up to an additional $435 million in milestones.

Roche funds 67% of the global development costs of ITMN-191. The companies will co-commercialize the product in the United States and share profits on a 50/50 basis. InterMune will receive royalties outside the United States.

Roche has rights to other HCV protease inhibitor development candidates resulting from the research collaboration. The economic terms for ITMN-191 also apply to additional compounds that InterMune and Roche may develop and commercialize.

In early April 2008, InterMune reported top-line results in the four dose cohorts of treatment-naive patients in a Phase 1b multiple-ascending-dose (MAD) monotherapy trial of ITMN-191 in patients chronically infected with HCV genotype 1. ITMN-191 demonstrated significant and rapid viral kinetic activity and excellent safety and tolerability in all dosage regimens. Also in early April, InterMune announced that 13-week preclinical studies in rats and monkeys were successfully completed which were necessary before initiation of clinical studies in Phase 2 with longer treatment durations than those performed to date with ITMN-191.

In late May 2008, InterMune initiated
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014 Whitehouse Laboratories is ... the Morris County (New Jersey) Chamber of Commerce ... leading business organization in the North Jersey area, ... engage some key clients in the pharmaceutical and ... geographic area. Membership enables Whitehouse Laboratories a higher ...
(Date:11/26/2014)... 25, 2014 Continuing its award-winning streak, ... three prestigious MarCom Awards for outstanding creative achievement by ... Platinum MarCom Award, the organization’s top honor, in the ... Louis held in April of this year. The event ... attendees. Additionally, Nerium was awarded a Gold MarCom Award ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Miles Holder, ... joined the Graphel Carbon Products team as Sales/Marketing Manager. ... marketing, and customer service for the graphite industry. , ... to our team,” stated Dave Trinkley, VP of Market ... wide range of experience in the graphite industry, along ...
(Date:11/26/2014)... November 26, 2014 2014 Deep ... an in-depth research report on the Global Palmitic ... introduces Palmitic Acid, basic information, including definition, classification, ... and news analysis, etc. , For international ... Palmitic Acid market in China and other ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3
... (NYSE Amex: PTN ), a biopharmaceutical company developing ... and other indications, today announced results for its third quarter ... Following a meeting with the U.S. ... to the FDA for initiation of an at-home Phase 2 ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced ... demonstrating that treatment with pirfenidone, a novel antifibrotic and ... function, 6-minute walk test distance and progression-free survival (PFS) ... (IPF).  IPF is a rare and fatal lung disease ...
... 2011 Novavax, Inc. (Nasdaq: NVAX ) a ... Officer of Novavax, will be presenting at the NOBLE FINANCIAL ... at The Hard Rock Hotel, Hollywood, FL.  A live audio-only ... Company website at www.novavax.com under Investors/Events. ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 2Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 3Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 4Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 5Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 6Pirfenidone Phase 3 Results Published Today in The Lancet 2Pirfenidone Phase 3 Results Published Today in The Lancet 3Pirfenidone Phase 3 Results Published Today in The Lancet 4Pirfenidone Phase 3 Results Published Today in The Lancet 5Pirfenidone Phase 3 Results Published Today in The Lancet 6
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... low birth weight and preterm birth are linked to ... Findings published in the American College of Rheumatology (ACR) ... low birth weight and pre-term babies were not at ... adults. , According to the ACR, 27 million ... clinical OA. Symptoms of OA range from mild to ...
(Date:11/2/2014)... As a child, it was fascinating to put a ... shine through the hand. Washington University in St. Louis ... inside the body,s tissues to improve imaging of cancerous ... Wang, PhD, the Gene K. Beare Distinguished Professor of ... Science is applying a novel time-reversal technology that allows ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... 2012As global temperatures rise, the most threatened ecosystems are those ... from the nation,s Long Term Ecological Research (LTER) Network ... is striking," says Julia Jones, a lead author in a ... featuring results from more than 30 years of LTER, a ...
... are the most populous organisms on the planet. They ... habitats by means of genetic variations that provide the ... what scientists believe is a random mutation and exchange ... that sometimes confers an advantage, and which then becomes ...
... of Illinois researchers surveyed over 3,500 college applicants, more than ... obese men were more likely to underestimate their weight than ... in dealing with a weight problem is knowing that you ... of food science and human nutrition. The study is ...
Cached Biology News:Long-term research reveals causes and consequences of environmental change 2Long-term research reveals causes and consequences of environmental change 3Long-term research reveals causes and consequences of environmental change 4Study shows unified process of evolution in bacteria and sexual eukaryotes 2Study shows unified process of evolution in bacteria and sexual eukaryotes 3Misperception of weight is an important barrier to weight loss 2
... for IVF are designed for human in ... of setup and operation, and convenience. ... continuously displayed on the control panel. Our ... printed by way of the thermal printer ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
... MultiScribe Reverse Transcriptase is a recombinant ... transcriptase. MultiScribe Reverse Transcriptase is similar ... in its recommended usage. MuLV reverse ... polymerase that uses single-stranded RNA as ...
... European Collection of Cell Cultures (ECACC) in ... of the West of England, Bristol, UK, ... quality control of HER2, oestrogen and progresterone ... wax sections of formalin fixed, breast cancer ...
Biology Products: